Rossari Biotech · Material risks, their source context, and severity in the latest available quarter.
ConCallIQ research layer
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Availability of ethylene oxide continues to be a near-term constraint. Supplier expansion expected on-stream by Q3 FY27. Until then, EO availability could impact production, though company is managing through reactor fungibility and non-EO product scaling.
Management explicitly acknowledged that B2C performance is not playing out as expected. Considering divestment or exit of consumer business with expected ~₹150 crore valuation. Current losses continuing but moderating.
Analyst raised concern that PAT has been broadly flat at ~₹30 crore per quarter since Q4 FY23, with ROC at sub-15%. Management attributed this to capacity investments and margin compression but provided no specific timeline for improvement beyond 'next year' and Q3 FY27 EO normalization.
Despite board approval, no capex amount, project timeline, anchor customers, or product profile finalized. Analyst questioned the wisdom of expanding overseas without established export business or anchor customers. Management stated discussions ongoing with 2 potential customers but no binding agreements.
